9 completed, 7 withdrawn, 6 not yet recruiting, 2 recruiting. 10 Phase 3, 6 Not applicable, 3 Early Phase 1, 3 Phase 2, 2 Phase 1.
Follow Applied Biology, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Study of DA-020 for the Treatment of Chemotherapy Induced Alopecia DA-020, Placebo, DA-020 and Hyperforin - Chemotherapy Induced Alopecia, Chemotherapy Side Effects | Phase 1 / Phase 2 | Recruiting | Applied Biology, Inc. | 60 | 2026-05-16 | 2026-08-21 |
| Clinical Study of DA-001 as a Treatment for Hair Shedding Reduction and Hair Re-Growth DA-001, Placebo, Phenylephrine - Telogen Effluvium, Female Pattern Hair Loss | Phase 2 / Phase 3 | Not yet recruiting | Applied Biology, Inc. | 1120 | 2026-05-01 | 2026-04-13 |
| Pharmacokinetic Study of DA-020 DA-020 (0.1%), DA-020 (0.2%), DA-020 (0.5%) - Chemotherapy Induced Alopecia, Chemotherapy Side Effects | Early Phase 1 | Not yet recruiting | Applied Biology, Inc. | 60 | 2026-04-16 | 2026-04-13 |
| Clinical Study of DA-007 for the Treatment of Chemotherapy Induced Alopecia DA-007, Placebo - Chemotherapy Induced Alopecia, Chemotherapy Side Effects | Phase 3 | Not yet recruiting | Applied Biology, Inc. | 140 | 2025-10-10 | 2025-05-23 |
| Clinical Study of mTOR Inhibitor as a Treatment for Grey Hair (Canities) CS-002, Placebo Topical Solution - Canities, Grey Hair | Phase 1 / Phase 2 | Not yet recruiting | Applied Biology, Inc. | 100 | 2025-10-01 | 2025-09-10 |
| Pharmacokinetic Study of Topical Phenylephrine Phenylephrine - Chemotherapy Induced Alopecia, Chemotherapy Side Effects | Early Phase 1 | Recruiting | Applied Biology, Inc. | 24 | 2025-06-30 | 2025-10-03 |
| Clinical Study of CS-001 As a Treatment for Canities (Grey Hair) CS-001, Placebo Topical Solution - Canities, Grey Hair | Phase 3 | Not yet recruiting | Applied Biology, Inc. | 240 | 2025-06-15 | 2024-12-24 |
| Clinical Study of DA-002 and DA-005 As a Treatment for Hair Loss DA-005, Topical minoxidil 5%, DA-002 - Androgenetic Alopecia, Female Pattern Baldness | Phase 3 | Not yet recruiting | Applied Biology, Inc. | 516 | 2025-01-15 | 2024-12-19 |
| Clinical Study of Probiotic Treatment for Androgenetic Alopecia Daniel Alain Probiotic Treatment for Androgenetic Alopecia, Topical minoxidil 5% - Androgenetic Alopecia, Female Pattern Baldness | Phase 3 | Withdrawn | Applied Biology, Inc. | 2024-09-15 | 2024-10-15 | |
| Comparison of JW-100 and EUCRISA for the Treatment of Atopic Dermatitis JW-100, Eucrisa - Atopic Dermatitis | Phase 3 | Withdrawn | Applied Biology, Inc. | 2022-11-24 | 2022-12-19 | |
| Study to Investigate the Effectiveness of a Topical Cosmetic Formulation DA-OTC-002 DA-OTC-002 - Hair Diseases, Alopecia | Not applicable | Completed | Applied Biology, Inc. | 76 | 2022-11-18 | 2023-10-23 |
| Treatment for Post Acute COVID-19 Syndrome Pimozide 1 MG - Tinnitus, Subjective | Not applicable | Unknown | Applied Biology, Inc. | 50 | 2022-10-01 | 2022-08-22 |
| HC-1119 Adjuvant Treatment for Hospitalized COVID-19 Patients HC-1119, Placebo - COVID-19 Respiratory Infection | Phase 3 | Unknown | Applied Biology, Inc. | 602 | 2022-04-15 | 2022-02-18 |
| Proxalutamide Treatment for COVID-19 Patients in Intensive Care Unit Proxalutamide, Placebo - Covid19, SARS (Severe Acute Respiratory Syndrome) | Phase 3 | Withdrawn | Applied Biology, Inc. | 2021-02-08 | 2022-03-04 | |
| Proxalutamide Treatment for Hospitalized COVID-19 Patients Proxalutamide, Placebo - Covid19, SARS (Severe Acute Respiratory Syndrome) | Phase 3 | Completed | Applied Biology, Inc. | 645 | 2021-02-01 | 2021-06-24 |
| Proxalutamide Treatment for COVID-19 Female Outpatients Proxalutamide, Standard of Care - Covid19, SARS-CoV Infection | Phase 3 | Withdrawn | Applied Biology, Inc. | 2020-11-01 | 2022-03-04 | |
| Anti-Androgen Treatment for COVID-19 Proxalutamide, Standard of Care - COVID-19, SARS-CoV2 | Not applicable | Completed | Applied Biology, Inc. | 268 | 2020-10-21 | 2021-12-10 |
| COVID-19 In-vitro Diagnostic Test and Androgen Receptor Gene Expression COVID-19 Androgen Sensitivity Test (CoVAST) - Covid19, Androgen Receptor Gene Overexpression | Withdrawn | University of California, Irvine | 2020-08-13 | 2024-05-08 | ||
| HairDx Analytical Validation Study HairDx Sample Collection Kit - Hair Loss, Hair Loss/Baldness | Withdrawn | Applied Biology, Inc. | 2020-06-15 | 2021-07-21 | ||
| In-vitro Diagnostic Test to Predict COVID-19 Mortality and Disease Severity CAG length <22, CAG length >=22 - SARS-CoV 2, COVID | Withdrawn | Applied Biology, Inc. | 2020-05-01 | 2023-07-19 |
Showing 20 of 26. Sign in to see all of them.
Alopecia (9) · COVID-19 (6) · Severe Acute Respiratory Syndrome (4) · Dermatitis, Atopic (2) · Breast Neoplasms (1) · Bulbo-Spinal Atrophy, X-Linked (1) · Hair Diseases (1) · Prostatic Hyperplasia (1) · Prostatic Neoplasms (1) · Psoriasis (1) · Sexual Dysfunction, Physiological (1) · Sexual Dysfunctions, Psychological (1) · Tinnitus (1) · Vitiligo (1)
proxalutamide (4) · Minoxidil (2) · Phenylephrine (2) · Standard of Care (2) · Pimozide (1) · crisaborole (1) · enzalutamide (1) · hyperforin (1)
Brazil (8) · United States (8) · Italy (6) · Australia (2) · India (2) · Spain (1)
Andy Goren, MD (10) · John McCoy, PhD (4) · Flavio Cadegiani, MD (3) · Carlos Wambier, MD (2) · Daniel Fonseca, MD (2) · Flavio Grasso, MD (2) · Rodney Sinclair, MD (2) · Sharon Keene, MD (2) · Daniel Fonesca (1) · Flavio A Cadegiani, MD (1) · Michael Krychman, MD (1) · Natasha Mesinkovska, MD, PhD (1) · Rachita Dhurat, MD (1) · Sabina Herrera, MD (1)
PMID 32237190, PMID 32283245, PMID 32301221, PMID 32333494, PMID 34350193